Uta Erdbrügger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Uta Erdbrügger has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Hayrettin Yavuz
University of Virginia School of Medicine
5 shared publications Thu H. Le
Department of Medicine, Division of Nephrology, University of Rochester Medical Center, Rochester, NY, USA
4 shared publications- Joanne Lannigan
Flow Cytometry Support Services, LLC Alexandria Virginia USA
3 shared publications - Agnieszka Swiatecka-Urban
Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Va
2 shared publications - Charles J. Blijdorp
Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications - Dylan Burger
Kidney Research Centre Ottawa Hospital Research Institute Ottawa Ontario Canada
2 shared publications
Latest Publications
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (5) , F714-F724
Temporal dynamics of urinary extracellular vesicle excretion and cargo in healthy subjects over 24 h
Urinary extracellular vesicles (uEVs) are increasingly studied as biomarkers of kidney health, but little is known about the changes in their excretion and cargo over the day. In this 24-h study, fluctuations in uEV concentration and cargo were observed, with sodium chloride cotransporter (NCC) having a temporal pattern with a dip in signal at noon. The results highlight the importance of uEV collection timing and normalization approaches, such as creatinine, which is stably excreted over the day.
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (5) , F714-F724
Temporal dynamics of urinary extracellular vesicle excretion and cargo in healthy subjects over 24 h
Urinary extracellular vesicles (uEVs) are increasingly studied as biomarkers of kidney health, but little is known about the changes in their excretion and cargo over the day. In this 24-h study, fluctuations in uEV concentration and cargo were observed, with sodium chloride cotransporter (NCC) having a temporal pattern with a dip in signal at noon. The results highlight the importance of uEV collection timing and normalization approaches, such as creatinine, which is stably excreted over the day.
- Open Access
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F563-F587
Sex differences in urinary extracellular vesicles originating from the genitourinary system in health and disease
Urinary extracellular vesicles (uEVs) have risen to the forefront as a source of biomarkers in urine, a biofluid that can be obtained noninvasively in large quantities. These lipid bilayer-bound, anucleate particles contain molecular cargo that may reflect the pathology of disease processes affecting the urogenital and reproductive systems. Urinary EVs can be derived from a variety of organs including the kidney, bladder, and urethra, as well as the testis, epididymis, vas deferens, prostate, and seminal vesicles in males, or the uterus, vagina, and placenta (during pregnancy) in females, as well as from microbiota present in the bladder or urogenital tract, leading to differences in biomolecular cargo based on sex. Hormonal cycles, circadian rhythms, age, and stress might further influence sex differences in uEVs. Despite growing interest in uEVs as biomarkers for renal and urological diseases, the majority of clinical studies to date have relied on urine samples from male-dominant cohorts, including investigations of sex chromosome-linked disorders. This sampling bias has contributed to a significant knowledge gap regarding sex-specific differences in uEV composition and function, which may critically influence disease mechanisms, diagnostic accuracy, and therapeutic targeting. Addressing this gap is essential for advancing the translational relevance and inclusivity of uEV-based research. This state-of-the-art review focuses on the current literature comparing male versus female uEVs using a variety of orthogonal methods across different studies. We also provide insights to address variability and improve rigor and reproducibility in uEV studies targeting both men’s and women’s health disorders, to move this field forward.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F563-F587
Open AccessSex differences in urinary extracellular vesicles originating from the genitourinary system in health and disease
Urinary extracellular vesicles (uEVs) have risen to the forefront as a source of biomarkers in urine, a biofluid that can be obtained noninvasively in large quantities. These lipid bilayer-bound, anucleate particles contain molecular cargo that may reflect the pathology of disease processes affecting the urogenital and reproductive systems. Urinary EVs can be derived from a variety of organs including the kidney, bladder, and urethra, as well as the testis, epididymis, vas deferens, prostate, and seminal vesicles in males, or the uterus, vagina, and placenta (during pregnancy) in females, as well as from microbiota present in the bladder or urogenital tract, leading to differences in biomolecular cargo based on sex. Hormonal cycles, circadian rhythms, age, and stress might further influence sex differences in uEVs. Despite growing interest in uEVs as biomarkers for renal and urological diseases, the majority of clinical studies to date have relied on urine samples from male-dominant cohorts, including investigations of sex chromosome-linked disorders. This sampling bias has contributed to a significant knowledge gap regarding sex-specific differences in uEV composition and function, which may critically influence disease mechanisms, diagnostic accuracy, and therapeutic targeting. Addressing this gap is essential for advancing the translational relevance and inclusivity of uEV-based research. This state-of-the-art review focuses on the current literature comparing male versus female uEVs using a variety of orthogonal methods across different studies. We also provide insights to address variability and improve rigor and reproducibility in uEV studies targeting both men’s and women’s health disorders, to move this field forward.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (5) , F690-F702
Pannexin channels in the kidney
Renal dysfunction leads to critical health conditions, including acute kidney injury (AKI) and chronic kidney disease (CKD), and is a driver of hypertension. Despite their global prevalence and impact, the pathophysiology for all kidney disease subtypes is incompletely understood; therefore, many patients progress to kidney failure, needing dialysis and transplantation. This review highlights the role of pannexins—a family of channel-forming glycoproteins—in renal physiology and pathophysiology. Compared with other organ systems such as the brain and cardiovascular system, relatively little is known about the function of pannexins in the kidney. However, recent findings indicate that pannexins may be potential therapeutic targets in the treatment of hypertension, AKI, and CKD, though further research is needed to fully understand their precise role in renal health and disease.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (5) , F690-F702
Pannexin channels in the kidney
Renal dysfunction leads to critical health conditions, including acute kidney injury (AKI) and chronic kidney disease (CKD), and is a driver of hypertension. Despite their global prevalence and impact, the pathophysiology for all kidney disease subtypes is incompletely understood; therefore, many patients progress to kidney failure, needing dialysis and transplantation. This review highlights the role of pannexins—a family of channel-forming glycoproteins—in renal physiology and pathophysiology. Compared with other organ systems such as the brain and cardiovascular system, relatively little is known about the function of pannexins in the kidney. However, recent findings indicate that pannexins may be potential therapeutic targets in the treatment of hypertension, AKI, and CKD, though further research is needed to fully understand their precise role in renal health and disease.
- Open Access
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5585
Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5585
Open AccessDiagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- Open Access
- 24 June 2025
- Published by MDPI AG in Preprints.org
Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- 24 June 2025
- Published by MDPI AG in Preprints.org
Open AccessDiagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.
- 4 February 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (2) , 112-115
PH and CKD: unravelling the cardiorenal nexus
- 4 February 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (2) , 112-115
PH and CKD: unravelling the cardiorenal nexus
- Open Access
- 22 November 2024
- Published by Wiley in Journal of Extracellular Biology
- Vol. 3 (11) , e70022
Uromodulin and the study of urinary extracellular vesicles
Urinary extracellular vesicles (uEVs) are a promising substrate for discovering new biomarkers. In order to investigate the origin of uEVs and the cargo they carry, some types of downstream analysis of uEVs may require concentration and enrichment as well as removal of contaminating substances. Co‐isolation of the abundant urinary protein uromodulin with uEVs can be a problem, and may interfere with some techniques, in particular with proteomic analysis tools. Methods of separating out uromodulin and its removal have also not been standardized. This review highlights aspects of uromodulin structure that makes it recalcitrant to separation from uEVs, summarizes frequently used techniques for uEV enrichment and how they affect uromodulin separation, and specific methods for uromodulin removal during preparation of uEVs. The necessity of uromodulin removal for various study endpoints is also examined.
- 22 November 2024
- Published by Wiley in Journal of Extracellular Biology
- Vol. 3 (11) , e70022
Open AccessUromodulin and the study of urinary extracellular vesicles
Urinary extracellular vesicles (uEVs) are a promising substrate for discovering new biomarkers. In order to investigate the origin of uEVs and the cargo they carry, some types of downstream analysis of uEVs may require concentration and enrichment as well as removal of contaminating substances. Co‐isolation of the abundant urinary protein uromodulin with uEVs can be a problem, and may interfere with some techniques, in particular with proteomic analysis tools. Methods of separating out uromodulin and its removal have also not been standardized. This review highlights aspects of uromodulin structure that makes it recalcitrant to separation from uEVs, summarizes frequently used techniques for uEV enrichment and how they affect uromodulin separation, and specific methods for uromodulin removal during preparation of uEVs. The necessity of uromodulin removal for various study endpoints is also examined.
- 18 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (2) , 245-257
Extracellular Vesicles in Kidney Diseases: Moving Forward
Extracellular vesicles (EVs) are evolving as novel cell mediators, biomarkers, and therapeutic targets in kidney health and disease. They are naturally derived from cells both within and outside the kidney and carry cargo which mirrors the state of the parent cell. Thus, they are potentially more sensitive and disease-specific as biomarkers and messengers in various kidney diseases. Beside their role as novel communicators within the nephron, they likely communicate between different organs affected by various kidney diseases. Study of urinary EVs (uEVs) can help to fill current knowledge gaps in kidney diseases. However, separation and characterization are challenged by their heterogeneity in size, shape, and cargo. Fortunately, more sensitive and direct EV measuring tools are in development. Many clinical syndromes in nephrology from acute to chronic kidney and glomerular to tubular diseases have been studied. Yet, validation of biomarkers in larger cohorts is warranted and simpler tools are needed. Translation from in vitro to in vivo studies is also urgently needed. The therapeutic role of uEVs in kidney diseases has been studied extensively in rodent models of AKI. On the basis of the current exponential growth of EV research, the field of EV diagnostics and therapeutics is moving forward.
- 18 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (2) , 245-257
Extracellular Vesicles in Kidney Diseases: Moving Forward
Extracellular vesicles (EVs) are evolving as novel cell mediators, biomarkers, and therapeutic targets in kidney health and disease. They are naturally derived from cells both within and outside the kidney and carry cargo which mirrors the state of the parent cell. Thus, they are potentially more sensitive and disease-specific as biomarkers and messengers in various kidney diseases. Beside their role as novel communicators within the nephron, they likely communicate between different organs affected by various kidney diseases. Study of urinary EVs (uEVs) can help to fill current knowledge gaps in kidney diseases. However, separation and characterization are challenged by their heterogeneity in size, shape, and cargo. Fortunately, more sensitive and direct EV measuring tools are in development. Many clinical syndromes in nephrology from acute to chronic kidney and glomerular to tubular diseases have been studied. Yet, validation of biomarkers in larger cohorts is warranted and simpler tools are needed. Translation from in vitro to in vivo studies is also urgently needed. The therapeutic role of uEVs in kidney diseases has been studied extensively in rodent models of AKI. On the basis of the current exponential growth of EV research, the field of EV diagnostics and therapeutics is moving forward.
- 30 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (1) , 48-51
Extracellular Vesicles in Acute Kidney Injury
Extracellular vesicles (EVs) are promising novel cellular communicators and biomarkers in acute kidney injury (AKI). These submicron vesicles derive from all cell types along the urinary tract and reflect molecular processes of their parent cells and physiological and pathological conditions in AKI. Several EV protein and RNA biomarker candidates have been identified. They have shown to differentiate AKI etiology and pinpoint to disease mechanisms. In fact, EV research has opened up a new frontier of biomarker discovery since some less abundant biomarkers are concentrated in EVs, which makes them more easily detectable. EVs are also functional and are involved in intra-nephron communication. Tubular-interstitial communication is current focus in EV research in AKI as it can help to understand maladaptive processes in AKI. EVs are also promising therapeutic tools and have been shown to be regenerative in many different models of AKI. Rigorous studies are needed to validate these findings, and more sensitive EV detection and characterization tools need to be developed to dissect EV biology in renal disease and AKI.
- 30 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (1) , 48-51
Extracellular Vesicles in Acute Kidney Injury
Extracellular vesicles (EVs) are promising novel cellular communicators and biomarkers in acute kidney injury (AKI). These submicron vesicles derive from all cell types along the urinary tract and reflect molecular processes of their parent cells and physiological and pathological conditions in AKI. Several EV protein and RNA biomarker candidates have been identified. They have shown to differentiate AKI etiology and pinpoint to disease mechanisms. In fact, EV research has opened up a new frontier of biomarker discovery since some less abundant biomarkers are concentrated in EVs, which makes them more easily detectable. EVs are also functional and are involved in intra-nephron communication. Tubular-interstitial communication is current focus in EV research in AKI as it can help to understand maladaptive processes in AKI. EVs are also promising therapeutic tools and have been shown to be regenerative in many different models of AKI. Rigorous studies are needed to validate these findings, and more sensitive EV detection and characterization tools need to be developed to dissect EV biology in renal disease and AKI.